Hydregen

HydRegen’s industrial biotechnology platforms deliver sustainable, safe and cost-efficient chemical processes. Partnerships with major chemicals companies have validated these technologies as ‘slot in’ replacements to precious metal catalysts, in existing chemical manufacturing infrastructure, providing a route to fast-tracking adoption of more sustainable bio-based manufacturing across the chemical sectors (current joint development projects in specialty, personal care, materials, and generics). By combining the benefits of milder biological conditions within intensified chemical infrastructure, we unlock at least 3xCO2e and 40% cost savings to our customers. We are now looking to raise £5-8m, focusing on delivering our first product (Bio2Amine) to a first 38 processes, with an end-market of £80bn and opportunity to HydRegen of £105m reoccurring revenue, before ramping our follow on products into additional markets. For Investors: https://hydregenoxford.com/investors